Trials / Recruiting
RecruitingNCT06331455
Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection
Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Marc de Perrot · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung cancer (NSCLC) prior to surgery. Patients who are enrolled in this trial will receive combination of Non-ablative oligofractionated radiation (NORT) and two cycles of Durvalumab, an immunotherapy drug before their surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab | Two doses of durvalumab (1500 mg IV) |
| RADIATION | Non-ablative oligofractionated radiation (NORT) | 12 Gy of Radiation in 3 fractions |
Timeline
- Start date
- 2024-05-22
- Primary completion
- 2025-12-01
- Completion
- 2026-04-01
- First posted
- 2024-03-26
- Last updated
- 2024-07-22
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06331455. Inclusion in this directory is not an endorsement.